InTechOpen uses cookies to offer you the best online experience. By continuing to use our site, you agree to our Privacy Policy.

Medicine » Endocrinology and Metabolism » "Thyroid and Parathyroid Diseases - New Insights into Some Old and Some New Issues", book edited by Laura Sterian Ward, ISBN 978-953-51-0221-2, Published: March 7, 2012 under CC BY 3.0 license. © The Author(s).

Chapter 8

Estrogen Signaling and Thyrocyte Proliferation

By Valeria Gabriela Antico Arciuch and Antonio Di Cristofano
DOI: 10.5772/35913

Article top

Role of estrogen in thyrocyte proliferation and in the development of follicular carcinomasEstrogen Signaling and Thyrocyte Proliferation

Valeria Gabriela1, Antico Arciuch and Antonio Di Cristofano

1. Introduction

The development of thyroid cancer is a multifactorial and multistep process. Several issues factors are thought to predispose people to thyroid cancer, including genetics, environment, and sex hormones. The incidence of thyroid cancer is three to four times higher in women that than in men (Libutti, 2005; Machens et al., 2006). This difference in incidence between genders suggests that the growth and outcome of thyroid tumors may be influenced by female sex hormones, particularly E2, which has been widely implicated in the development and progression of several cancers, such as breast, ovarian and prostate cancer (Arnold et al., 2007; Stender et al., 2007). Animal studies support these epidemiological data, and suggest that exogenous estrogen (17β-estradiol, E2) can promote thyroid tumors (Mori et al., 1990; Thiruvengadam et al., 2003).

Several studies have been carried out to address the pathological role of estrogens in the pathogenesis of proliferative and neoplastic disordersmalignancies. Although the precise mechanism still remains obscureill-defined, a range of plausible mechanisms to elucidateexplaining their carcinogenic effects has arosebeen proposed. On one hand, estrogens may promote cellular proliferation through their receptor-mediated activity (Arnold et al., 2007; Lee et al., 2005). In addition, the natural estrogen E2 or its metabolites 2- hydroxy, 4-hydroxy, and 16-α-hydroxy-estradiol (2-OH-E2, 4-OH-E2, and 16-α-OH E2) can directly cause neoplastic transformation through a direct genotoxic effect, increasing the spontaneous mutation rate. of normal cells The neoplastic transformation induced by E2 is anchorage independent since neither tamoxifen or estrogen antagonists can disrupt the transforming effect of estrogen (Cavalieri et al., 1997; Fernandez et al., 2005).

In this review, we will analyze the role of estrogen signaling in the proliferation and transformation of the thyroid gland, with a special emphasis on the cross-talk between estrogen signaling and the PI3K pathway.Furthermore, estrogens may generate a direct genotoxic effect to increase mutation rates through a cytochrome-mediated metabolic activation (Chakravarti et al., 2001; Herrmann et al., 2002). Although estrogens are deeply involved in the carcinogenesis, deconstructing the pathway is complex and poorly understood, especially in the case of thyroid cancer.

2. Thyroid proliferative disorders and cancer

Thyroid carcinoma is the most common and prevalent of all endocrine malignancies, accounting for more than 95% of all endocrine-related cancers (Hodgson et al., 2004; Jemal et al., 2009). Papillary and follicular carcinomas (PTC and FTC respectively) are Ddifferentiated tumors include those arising from thyroid epithelial cells (thyrocytes), i.e. papillary and follicular carcinoma (PTC and FTC respectively),, while medullary carcinoma originates from parafollicular cells. PTC is by far the most common type of thyroid cancer, representing up to 80% of all thyroid malignancies. Anaplastic carcinomas ares undifferentiated tumors deriving from thyroid epithelial cells. They are usually lethal with no effective system therapy. The factors leading to thyroid carcinoma development are not fully understood despite some well well-established associations, such as between ionizing radiation and papillary carcinoma, and between iodine deficiency and follicular carcinoma.

From the molecular point of view, papillary and follicular thyroid cancers are completely different diseases. This notion is supported by the dissimilar molecular initiating events leading to neoplastic transformation and by the differences in DNA ploidy level (PTCs are generally diploid, FTCs aneuploid) (Handkiewicz-Junak et al., 2010).

Follicular CarcinomaPapillary CarcinomaAnaplastic Carcinoma
RAS: 20-50%BRAF: 40-45%TP53: 50-80%
PAX8-PPARγ: 20-35%RAS: 10-20%BRAF: 20-40%
PI3K pathway: 20%RET-PTC: 10-30%RAS: 20-40%
PI3K pathway: 20-50%

Table 1.

Most frequent genetic alterations in thyroid cancer

By far the most common type of thyroid cancer is PTC, representing up to 80% of all thyroid malignancies. The gross appearance of papillary thyroid cancer is quite variable. The lesions may appear anywhere within the gland. By definition, typical papillary carcinomas often average 2–3 cm, although lesions may be quite large or commonly subcentimeter in size. The lesions are firm and usually white in color with an invasive appearance and lesional calcification is a common feature (Livolsi, 2011). The genetic alterations found in PTC primarily affect two central signalling pathways in thyroid cells: TSH receptor (TSHR)-mediated signalling and mitogen-activated protein kinase (MAPK) pathways (Kim and Zhu, 2009; Lemoine et al., 1998; Nikiforov, 2008). Three important initiating events, RET/PTC (rearranged during transfection/ papillary thyroid cancer), RAS (resistance to audiogenic seizures) and BRAF mutations, are considered mutually exclusive and alternative trigger the activation of the pathway leading to PTC (Fagin, 2004). A single oncogenic alteration along the receptor tyrosine kinase–RAS–RAF–MEK–ERK1/2 pathway is likely sufficient to drive thyroid cell neoplastic transformation, although further molecular events are necessary. BRAF mutation and RET/PTC rearrangements differ to some extent in their effects on the shared oncogenic pathway, respectively, resulting more frequently in the classic or the solid variant of PTC, respectively,, while RAS mutations are more likely to induce the follicular variant of PTC (Xing, 2005). ).

Follicular carcinomas are often characterized by RAS mutations (up to 50%) and PAX8-PPARγ rearrangements (20–35%), which lead to a mutant protein incapable of trans-activating a PPARγ signal (Gilfillan, 2010). The pPhosphatidylinositol 3-kinase (PI3K)/AktAKT alterations are frequently found in every histotype of thyroid cancer, frequently in FTC and, even more distinctly, in ATC. In FTC, phosphorylation of AKT, the key player in this pathway, is by far more frequent than that of ERK (Liu et al., 2008).

Although aAnaplastic thyroid carcinomas (ATCs) comprise 2% of thyroid malignancies, they and are usually lethal, with no effective system therapy. The rapid onset and median survival of around 4 months have not changed in more than half a century due to uncontrolled metastases mainly to the lungs and to less extent, to bones, skin and brain (Are and Shaha, 2006). Dedifferentiation, a common hallmark of ATC, is manifested by a loss of specific thyroid cell characteristics and functions, including expression of thyroglobulin, thyroid peroxidase, thyroid stimulating hormone receptor and the Na/I symporter (Neff et al., 2008; Smallridge et al., 2009). Molecular signature events that characterize ATC involve either dual BRAF activation of both pathways or sustained hyperactivation of the PI3K/AktAKT cascade, together with TP53 loss or inactivation (Kouniavsky and Zeiger, 2010).

The incidence of thyroid proliferative disorders and malignancies is three to four times higher in women, suggesting that estrogen contributes to thyrocyte’s growth, migratory and invasive properties. Both the thyrocyte proliferation rate and the adenoma incidence are much higher in PtenL/L;TPO-Cre females than in males (Yeager et al., 2007), mimicking the well-established higher prevalence of thyroid disorders among women (Libutti, 2005). Furthermore, estrogen depletion reduces the thyroid proliferative index of mutant females to the same levels observed in mutant males, while estrogen stimulation increases the thyroid proliferative index of mutant males to the same levels observed in mutant females (Antico Arciuch et al., 2010).

3. Physiological functions of estrogen and estrogen receptors

3.1. Estrogen production

Estrogens are a group of steroid compounds acting as the primary female sex hormones. Estrogens regulate several physiological processes, including cell growth and development, not only in the reproductive tract but also in other tissues such as bone, brain, liver, cardiovascular system, and endocrine glands.

Although estrogens are present in both men and women, their levels are significantly higher in women of reproductive age. They are mainly produced by the adrenal cortex and ovary. The three major naturally occurring estrogens in women are: estrone, estradiol and estriol (Speroff et al., 1999). In premenopausal women, 17β-estradiol (E2), produced by the ovary, is the estrogen formed in the largest quantity and is the most potent since it has the highest affinity for estrogen receptors. In premenopausal women, the level of circulating E2 varies from 40 to 400 pg/mL during the menstrual cycle (Ruggiero et al., 2002). After menopause, the level of E2 drops to less than 20 pg/mL (Jones, 1992). The second endogenous estrogen is estrone (E1), a less potent metabolite of E2. Estrone is produced from androstenedione in adipose tissue. In postmenopausal women, the ovary ceases to produce E2 while the adrenal gland continues to produce androstenedione, with the result that the level of estrone remains unchanged while the level of E2 falls significantly. The third endogenous estrogen is estriol (E3), also a metabolite of E2. E3 is the main estrogen produced by the placenta during pregnancy, and is found in smaller quantities than E2 and E1 in nonpregnant women (Jones, 1992; Ruggiero et al., 2002). Besides the adrenal cortex and ovary, the human thyroid gland also has ability to synthesize estrogens and such ability seems to be higher in women than men (Dalla Valle et al., 1998).

Estrogens regulate several physiological processes including cell growth and development not only in the reproductive tract but also in other tissues such as bone, brain, liver, cardiovascular system and endocrine glands. In the thyroid gland, E2 provokes a considerable increase in the thyroid weight (Lima et al., 2006). In addition, it stimulates thyroid iodide uptake, enhances thyroperoxidase activity and increases the level of T3 (Lima et al., 2006).

3.2. Estrogen receptors and their ligands

The actions of estrogens occur through activation of estrogen receptors (ERα, ERβ and GPR30). ERα was initially described in 1973 (Jensen and De Sombre, 1973) while ERβ was identified much later (Kuiper et al., 1996). ERα and ERβ are encoded by separate genes, ESR1 and ESR2, respectively, but both genes are homologouswhich share similarities in the DNA-binding domain (97% amino acid similarity) and ligand-binding domain (60% amino acid similarity) (Hall et al., 2001). These two ERs differ in their tissue distributions (Kuiper et al., 1997; Dechering et al., 2000), suggesting that ERα and ERβ might have different physiological functions. It has also been demonstrated that in many systems the activity of ERβ is opposed to that of ERα. For example, in breast cancer cells, ERα is the receptor responsible for E2-induced proliferation, whereas activation of ERβ inhibits this effect (Strom et al., 2004). In the uterus, E2 induces proliferation of both epithelial and stromal cells through ERα, which is the predominant ER in the mature organ, while in the immature uterus, ERα and ERβ are found at similar expression levels in both epithelium and stroma, and ERβ mediates the action of E2 as a suppressor of cell proliferation against activation of ERα by E2 (Weihua et al., 2000).

G protein-coupled receptor 30 (GPR30), a novel transmembrane ER, was identified in different cells by four laboratories during between 1996 and 1998 (Takada et al., 1997; Owman et al., 1996; Carmeci et al., 1997; O’Dowd et al., 1998). Since its ligand was unknown at that time, it was named based on its homology to the G protein-coupled receptor (GPCR) super-family. In addition, this receptor was found to be associated with ER expression in breast cancer cell lines (Carmeci et al., 1997). Later in 2000, Filardo et al. demonstrated that estrogen promptly activated ERK1/2 in two breast cancer cell lines, MCF-7 and SKBR3, with the cell line SKBR3 non-expressing ERs. These results demonstrated that estrogen might be a potential ligand for GPR30 (Filardo et al., 2000). This fact was further confirmed by the observation that estrogen did not active activate ERK1/2 in the breast cancer cell line MDA-MB-231 without GPR30 expression, whereas ERK1/2 was activated by estrogen after GPR30 transfection into the cells (Filardo et al., 2000). Therefore, GPR30 is necessary for the activation of ERK1/2 by estrogen. So far, GPR30 has been detected in numerous human tissues such as heart, liver, lung, intestine, ovary, brain, breast, uterus, placenta and prostate (He et al., 2009; Filardo et al., 2006; Zhang et al., 2008; Haas et al., 2007; Hugo et al., 2008).

3.3. Genomic and non-genomic actions of estrogen receptors

In the classical, genomic estrogen-signaling pathway, estradiol (E2)-activated ERα translocates to the nucleus, dimerizes, and binds to the 15-bp palindromic estrogen response element (ERE) or interacts with other transcription factors on target genes, recruits coactivators, and stimulates gene transcription thereby promoting cell proliferation (Klinge, 2000). ERα interacts with a number of coactivators and corepressors in a ligand-dependent manner (Klinge, 2000). ERα may also function in a non-traditional manner, interacting with other DNA-binding transcription factors such as activator protein 1 (AP-1) or Sp-1, that in turn bind their cognate DNA elements, leading to remodeling of chromatin, and interactions with components of the basal transcription machinery complex (Ascenzi et al., 2006; Deroo and Korach, 2006).

Another more rapid mechanism of estrogen action is termed ‘non-genomic’ or ‘membrane-initiated’ because it involves E2 activation of plasma membrane membrane-associated ERα or ERβ and leads to rapid activation of intracellular signaling pathways, e.g., ERK1/2 and PI3K/AktAKT (Wong et al., 2002; Watson et al., 2007; He et al., 2009). It can also result in an increase of Ca2+ or nitric oxide and the promotion of cell cycle progression. The ERs may be targeted to the plasma membrane by adaptor proteins such as caveolin-1 or Shc (Kim et al., 2008). GPR30 is a novel membrane estrogen receptor that also activates ERK1/2 and PI3K/AktAKT signaling, although its exact role in estrogen action remains controversial (Pedram et al., 2006). GPR30 ligands, for example, estrogen (Muller et al., 1979), tamoxifen (Dick et al., 2002) and ICI 182780 (Hermenegildo and Cano, 2000) may bind to GPR30, and activate heterotrimeric G proteins, which then activate Src and adenylyl cyclase (AC) resulting in intracellular cAMP production. Src is involved in matrix metalloproteinases (MMP) activation, which cleave pro-heparan-bound epidermal growth factor (pro-HB-EGF) and release free HB-EGF. The latter activates EGF receptor (EGFR), leading to multiple downstream events such as activation of phospholipase C (PLC), PI3K, and MAPK. Activated PLC produces inositol triphosphate (IP3), which further binds to IP3 receptor and leads to intracellular calcium mobilization. The activation of MAPK and PI3K results in activation of numerous cytosolic pathways and nuclear proteins, which further regulate transcription factors such as serum response factor and members of the E26 transformation specific (ETS) family by direct phosphorylation (Posern and Treisman, 2006; Gutierrez-Hartmann et al., 2007).

The non-genomic pathway may cross-talk with the genomic pathway, since ERαEra can be translocated from the membrane into the nucleus both in a E2-dependent or independent manner (Lu et al., 2002). It has also been demonstrated that E2-induced ERK activation stimulates the expression of AP-1-mediated genes via both serum response factor ELK-1 (ER activated in the membrane) and the recruitment of coactivators to AP-1 sites on gene promoters by the nuclear ER (Ascenzi et al., 2006). The intricate relationship between membrane and nuclear effects induced by estrogens has also been observed in the regulation of many other genes including PI3K (Ascenzi et al., 2006).

Therefore, integrative signaling by E2 from several places in the cell can lead to both rapid and sustained actions, which synergize to provide plasticity for cell response.

3.4. Estrogen receptors in the mitochondria

It was previously described that eGlucocorticoid and thyroid hormones have been shown to modify the levels of mtDNA-encoded gene transcripts. These effects are mediated through direct interactions of their receptors with mtDNA. It has also been established that thyroid hormone can cause the direct stimulation of mitochondrial RNA synthesis (Casas et al., 1999; Enriquez et al., 1999) and that a variant form of the thyroid hormone receptor is imported in and localized within liver mitochondria (Casas et al., 1999; Wrutniak et al., 1995).

These findings suggest that mitochondria could also be one a target site for the action of estrogens. Monje and colleagues (Monje and Boland 2001; Monje et al., 2001) demonstrated the presence of both ERα and ERβ in mitochondria of rabbit uterine and ovarian tissue, and ER translocation into mitochondria suggests the presence of E2 effects on mitochondrial function and protein expression (Chen et al., 2004). The mitochondrial genome also contains estrogen response elements (ERE)-like sequences (Demonacos et al., 1996; Sekeris et al., 1990). Furthermore, several studies have detected the presence of estrogen-binding proteins (EBPs) in the organelle (Grossman et al., 1989; Moats and Ramirez 2000). Estrogen treatment increases the transcript levels of several mitochondrial DNA (mtDNA)-encoded genes in rat hepatocytes and human Hep G2 cells (Chen et al., 1996; Chen et al., 1998).

Estrogen response elements have been found in the D-loop, in the master regulatory region, and within the structural genes of the mtDNA (Demonacos et al., 1996). As a consequence, E2 may exert coordinated effects on both nuclear and mitochondrial gene expression. Previous studies showed that E2 can increase mtDNA transcripts for cytochrome oxidase IV subunits I and II in cultured cancer cells (Chen et al., 2004). E2 profoundly affects mitochondrial function in cerebral blood vessels, enhancing efficiency of energy production and suppressing mitochondrial oxidative stress by increasing protein levels of Mn-SOD and aconitase, and stabilizing mitochondrial membrane (Stirone et al., 2005).

The mechanisms of ER translocation into mitochondria are still quite elusive but recent data on in MCF7 cells demonstrated that human ERβ posses a putative internal mitochondrial targeting peptide signal to the organelle (Chen et al., 2004). These authors observed that around 12% of total cellular ERα and 18% of ERβ is present in the mitochondrial fraction in E2-treated MCF7 cells. Furthermore, the localization of both ERα and ERβ to mitochondria in response to E2-treatment is accompanied by a concominantconcomitant -time- and concentration-dependent increase in the transcript levels of the mtDNA-encoded genes (Chen et al., 2004).

3.5. Target molecules of estrogen receptors in the thyroid gland

Besides the adrenal cortex and ovary, also the human thyroid gland has the ability to synthesize estrogens and such ability seems to be higher in women than men (Dalla Valle et al., 1998). In the thyroid gland, E2 provokes a considerable increase in the thyroid weight, stimulates thyroid iodide uptake, enhances thyroperoxidase activity, and increases the level of T3 (Lima et al., 2006).

ERK1/2 regulate various cellular activities, such as gene expression, mitosis, differentiation, proliferation, and cell survival/apoptosis (Roberts and Der, 2007; Dunn et al., 2005). Zeng and colleagues have demonstrated that E2 can activate ERK1/2 in the thyroid by inducing its phosphorylation (Zeng et al., 2007). ERK1/2 activation by E2 depends on the interaction between estradiol and ERα (Zeng et al., 2007).

Bcl-2 family proteins play a central role in controlling mitochondrial-mediated apoptosis. They include proteins that suppress apoptosis such as Bcl-2 and Bcl-XL, and proteins that promote apoptosis such as Bax, Bad and Bcl-XS (Antonsson and Martinou, 2000). Bcl-2 proteins localize or translocate to the mitochondrial membrane and modulate apoptosis by permeabilization of the inner and/or outer membrane, leading to the release of citochrome c or stabilization of the barrier function. Bcl-2 family members are altered in thyroid cancer (Kossmehl et al., 2003) and their levels are regulated by estrogen in some cell systems (Song and Santen, 2003). The antiapoptotic member Bcl-2 is up-regulated by E2 and by the ERα agonist PPT, but down-regulated by the ERβ agonist DPN in thyroid cancer cells, suggesting that ERα induces Bcl-2 expression whereas ERβ reduces it (Zeng et al., 2007). In addition, the authors demonstratedit has been shown that ERβ but not ERα promotes the expression level of Bax (Lee et al., 2005; Zeng et al., 2007).

Mitogen-activated protein kinases (MAPKs) are able to convert extracellular stimuli to intracellular signals that regulate various cellular activities, such as gene expression, mitosis, differentiation, proliferation, and cell survival/apoptosis (Roberts and Der, 2007; Dunn et al., 2005). Since activated MAPKs integrate several biological processes, they are also key molecules in the regulation of cell growth and apoptosis of a number of cancers including thyroid cancer (Chen et al., 2004; Lui et al., 2007; Lin et al., 2007). Zeng and colleagues have demonstrated that E2 can activate ERK1/2 by inducing its phosphorylation (Zeng et al., 2007). ERK1/2 activation by E2 occurs mainly due to the interaction between estradiol and ER Therefore, ERK1/2 activation by E2 is positively associated with ER in thyroid cancer cells. (Zeng et al., 2007).

Recent work on the WRO thyroid cancer cells revealed that E2 increases cathepsin D transcription and that cathepsin D expression is inhibited upon siRNA-mediated knockdown of ERα and ERβ (Kumar et al., 2010). Cathepsin D is a classical E2 target gene regulated by Sp1-ERα promoter binding (Wang et al., 1997). It is well established that cathepsin D expression is elevated in thyroid tumors and correlates with disease aggression aggressiveness (Leto et al., 2004).

The expression of another classical E2 target gene, cyclin D1 (Pestell et al., 1999), is stimulated by E2 in thyroid cancer cell lines, and co-treatment with siERα and siERβ shows roles for ERα and ERβ in regulating cyclin D1 transcription. E2 regulation of cyclin D1 transcription involves ERα-Sp1 interaction (Castro-Rivera et al., 2001) and AP-1-ERα (Liu et al., 2002) interactions.

In Nthy-ori3-1 and BCPAP cells (derived from thyroid carcinoma), ERα was found to be complexed with Hsp90 and AktAKT (Rajoria et al., 2010). The complex of Hsp90 and AktAKT with ERα has major implications for its non-genomic signaling. In the presence of E2, Hsp90 dissociates, allowing ERα to dimerize and induce gene expression. And At the same time, AktAKT is also rendered free to manifest and participate in the signal transduction cascade. These studies provide evidence for a link between estrogen and adhesion, invasion, and migration of thyroid cells.

Rajoria and colleagues observed that E2 dramatically increases the ability of thyroid cells to adhere dramatically (137-140%) and their migration as welle (27-75%). They also found a downregulation of βtumor suppressive protein, -catenin, in the thyroid cells treated with E2. As a whole, these data suggest a strong link between estrogen and TCa cell proliferation and metastatic phenotype as evidenced by its effect on in vitro adhesion, migration, and invasion (Rajoria et al., 2010).

4. PI3K-AktAKT pathway

In 1991, three independent research groups identified the gene that encodes for the serin/threonin kinase AktAKT/PKB (Jones et al., 1991; Bellacosa et al., 1991; Coffer and Woodgent, 1991). ). AktAKT plays a major role in cell proliferation, survival, adhesion, migration, metabolism and tumorigenesis. The critical effects of AktAKT activation are determined by the phosphorylation of its downstream effectors located in the cytoplasm, nucleus and mitochondria (Manning and Cantley, 2007; Bijur and Jope, 2003; Antico Arciuch et al., 2009). Mammals have three closely related PKB genes, encoding the isoforms AktAKT1/PKBα, AktAKT2/PKBβ and AktAKT3/PKBγ. Although the AktAKT isoforms are ubiquitously expressed, evidence suggests that the relative isoform expression levels differ between tissues. AktAKT1 is the mainly expressed isoform in most tissues, while AktAKT2 is highly enriched in insulin target tissues. AktAKTkt1 deficient mice show normal glucose tolerance and insulin-stimulated glucose clearance from blood, but display severe growth retardation (Cho et al., 2001). It has also been shown that cells derived from AktAKTkt1 deficient mouse embryos are also more susceptible to pro-apoptotic stimuli (Chen et al., 2001). On the other hand, deficiency of AktAKT2 alone is sufficient to cause a diabetic phenotype in mice (Withers et al., 1998; Cho et al., 2001) and a loss-of-function mutation in AktAKT2 is associated with diabetes in one human family (George et al., 2004).

AktAKT kinases are typically activated by engagement of receptor tyrosine kinases by growth factors and cytokines, as well as oxidative stress and heat shock. AktAKT activation relies on phosphatidylinositol 3,4,5-triphosphate (PtdIns-3,4,5-P3) which is converted produced from phosphatidylinositol 4,5-biphosphate (PtdIns-4,5-P2) by phosphatidylinositol 3-kinase (PI3K) (Franke et al., 1995). The interaction between the Pleckstrin homology (PH) domain of AKT of with PtdIns-3,4,5-P3 with the Pleckstrin homology (PH) domain of Akt1 favors the itsbinding with their upstream activators and it undergoes phosphorylation at two residues, one in the C-terminal tail (Ser473) and the other in the activation loop (Thr308). Phosphorylation at Ser473 appears to precede and facilitate phosphorylation at Thr308 (Sarbassov et al., 2005). AktAKT1 is phosphorylated in Ser473 by mTORC2 (Ikenoue et al., 2008), while PI-3K-dependent kinase 1 (PDK1) accounts for the phosphorylation in Thr308 (Chan et al., 1999).

The proliferative effects of AktAKT result from phosphorylation of several substrates.. For example, This is the case of GSK3β once phosphorylated gets is inactivated and this prevents degradation of cyclin D1 (Diehl et al., 1998), ). Furthermore, AKT activation as well asleads to increased translation of cyclin D1 and D3 transcripts via mTOR pathway (Muise-Helmericks et al., 1998). AktAKT phosphorylates the cell cycle inhibitors p21WAF1 and p27Kip1 inducing its their cytoplasmic retention (Testa and Bellacosa, 2001).

AktAKT activity prevents apoptosis through the phosphorylation and inhibition of pro-apoptotic mediators such as Bad, FOXO family members, and IκB kinase-β (IKK-β) (Datta et al., 1999). AktAKT activity also attenuates the response of cells to the release of cytochrome c into the cytoplasm (Kennedy et al., 1999).

AktAKT can also antagonize p53-mediated cell cycle checkpoints by modulating the subcellular localization of Mdm2. Phosphorylation of Mdm2 by AktAKT triggers its localization to the nucleus, where Mdm2 can complex with p53 to promote its ubiquitin/proteasome-mediated degradation (Mayo and Donner, 2001).

The crucial role of the PI3K signaling cascade in the pathogenesis of thyroid proliferative and neoplastic disorders has been recently confirmed by the development and study of a relevant mouse model (Yeager et al., 2007, 2008; Miller et al., 2009), as well as by solid clinicopathological data (Garcia-Rostan et al., 2005; Hou et al., 2007, 2008; Vasko and Saji, 2007; Wang et al., 2007). Thyrocyte-specific deletion of the Pten tumor suppressor constitutively activates the PI3K signaling cascade, leading to hyperplastic thyroid glands at birth, and to the development of thyroid nodules and follicular adenomas by 6-8 months of age (Yeager et al., 2007) and thyroid carcinomas by one year of age (Antico Arciuch et al., 2010).

5. PI3K-estrogen cooperation during proliferation

The Pten mouse model of thyroid disease displays a unique and remarkable characteristic: the higher proliferative index of female mutant thyrocytes, compared with males. This difference leads to increased cellularity in the thyroids of female mutants at a young age, to an increased incidence of thyroid adenomas in mutant females in the females at 8 months of age (Yeager et al., 2007), and to an increased incidence of thyroid carcinomas in mutant females at one year of age (Antico Arciuch et al., 2010). The direct role of estrogen signaling in determining this difference in proliferative response to PI3K activation is underlined by the fact that these effects could be completely reversed by estrogen depletion in the females, and by slow-release estrogen pellet implantation in the males.

Several groups had anticipated a role for estrogen in thyroid proliferation, based on the effects of estradiol on thyroid carcinoma cells in culture (Manole et al., 2001; Vivacqua et al., 2006; Chen et al., 2008; Kumar et al., 2010; Rajoria et al., 2010). The Pten mouse model represents the first in vivo validation of the direct role played by estrogen in establishing the increased prevalence of thyroid disorders in the female.


Figure 1.

Schematic model of the cooperation between estrogen signaling and PI3K activation.

. While these results support a key role for the PI3K pathway in the regulation of thyroid proliferative homeostasis, they also suggest that its constitutive activation is not sufficient for full neoplastic transformation. Accordingly, an oncogenic allele of Kras synergizes with Pten loss and leads to the rapid development of thyroid follicular carcinomas (Miller et al., 2009).

The analysis of Pten mutant mice also for up to 2 years not only reveals their high susceptibility to developing metastatic follicular carcinomas, but also shed some light on the molecular basis of the differential thyrocyte proliferative index and risk of adenoma and carcinoma development between male and female mutant mice. Genetic approaches, by crossing Pten mutant mice and p27 mutant mice, and cell culture-based experiments have provided evidence that these gender-based differences in this mouse model are due, at least in part, to the ability of estrogens to down-regulate p27 levels through mechanisms that include transcriptional regulation, in addition to the known effects on p27 protein degradation through regulation of Skp2 (Antico Arciuch et al., 2010; Foster et al., 2003).The noteworthy feature of this model is the increased tumor incidence in female mutants, mirroring the increased susceptibility of women to thyroid disorders. Several groups have anticipated a role for estrogen in thyroid proliferation, in accordance to the effects of estradiol on thyroid carcinoma cells in culture (Manole et al., 2001; Vivacqua et al., 2006; Chen et al., 2008; Kumar et al., 2010; Rajoria et al., 2010).

Thus it is conceivable that, in thyroids harboring mutations that confer elevated proliferative signals and thus a low cell cycle progression threshold, E2-mediated p27 depletion further increases the thyrocyte proliferative index (Figure 1).

Additional mechanisms, including E2-mediated mitochondrial effects, are also likely to contribute to this phenotype. Maintenance of a normal intracellular redox status plays an important role in such processes as DNA synthesis, gene expression, enzymatic activity, and others. Signaling cascades involving protein tyrosine kinases can be enhanced by oxidative inhibition of protein tyrosine phosphatases, and pathways involving NF-kB, JNK, p38 MAPK, and AP-1 are strongly responsive to redox regulation (Droge, 2002). Recent data have suggested that physiological concentrations of E2 trigger a rapid production of intracellular reactive oxygen species (ROS) in endothelial and epithelial cells, and that E2-induced DNA synthesis is at least in part mediated by ROS signaling in these cells (Felty et al., 2005; Felty, 2006). This notion is particularly intriguing, since E2-mediated ROS production in thyroid follicular cells would have two effects: an immediate stimulation of cell proliferation, and a long-term accumulation of oxidative DNA damage. Furthermore, these effects would be further enhanced if PI3K activation resulted in an alteration of the thyrocyte antioxidant and detoxification system. Strikingly, in an ongoing proteomic effort (manuscript in preparation), we have recently identified Glutathione S-transferase Mu 1 (GSTM1), an enzyme important for the reduction (detoxification) of hydrogen peroxide, as one of the most significantly down-regulated proteins in mutant thyroids, suggesting that, indeed, PI3K-mediated GSTM1 reduction might indeed further amplify the effects of ROS in the thyroid.

Recent studies have demonstrated for the first time that, in the context of PI3K activation, circulating estrogens increase thyroid follicular cells proliferation (Antico Arciuch, 2010). Finally, the increased expression level of Tpo, Duox1 and Slc5a5 genes in female mice, irrespective of their genotype, strongly suggests that estrogen has a significant role in their transcriptional regulation. In addition, the gender-based differences in thyrocyte proliferation and neoplastic transformation elicited by estrogens are due, at least in part, to the ability of these hormones to regulate p27 levels through mechanisms that include transcriptional regulation in addition to the known effects of estrogens on p27 protein degradation through Skp2 (Antico Arciuch, 2010; Foster et al., 2003)., providing additional targets for future studies on the role of estrogen in the pathophysiology of the thyroid gland.

6. Conclusion

A role for estrogen in thyroid proliferation has been proposed for several years, based on the analysis of the effects of estrogen on thyroid cells in culture. Now, for the first time, our hormone manipulation experiments in a relevant mouse model of thyroid proliferative disorders and neoplastic transformation have provided in vivo evidence that circulating estrogens increase thyroid follicular cells proliferation. It is tempting to suggest that the relatively mild effect of estrogens on thyroid cells is uncovered and amplified by oncogenic events lowering the thyrocyte proliferation threshold. Further studies will validate this hypothesis in the context of different oncogenic mutations.


1 - Arciuch. V. G. Antico, M. Dima, X. H. Liao, S. Refetoff, A. Di Cristofano, 2010 Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females. Oncogene. 29 567886 .
2 - Arciuch. V. G. Antico, S. Galli, M. C. Franco, P. Y. Lam, E. Cadenas, M. C. Carreras, J. J. Poderoso, 2009 AktAKT1 intramitochondrial cycling is a crucial step in the redox modulation of cell cycle progression. PLoS One 4: e7523.
3 - B. Antonsson, J. C. Martinou, 2000 The Bcl-2 protein family. Exp Cell Res. 256 507 .
4 - C. Are, A. R. Shaha, 2006 Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 13 45364 .
5 - J. T. Arnold, X. Liu, J. D. Allen, H. Le , K. K. Mc Fann, M. R. Blackman, 2007 Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate. 67 115262 .
6 - P. Ascenzi, A. Bocedi, M. Marino, 2006 Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med. 27 299402 .
7 - A. Bellacosa, J. R. Testa, S. P. Staal, P. N. Tsichlis, 1991 A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science. 254 274277 .
8 - G. N. Bijur, R. S. Jope, Rapid accumulation of AktAKT in mitochondria following phosphatidylinositol 3 activation. (2003) J Neurochem 87 142735 .
9 - C. Carmeci, D. A. Thompson, H. Z. Ring, U. Francke, R. J. Weigel, 1997 Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics. 45 607617 .
10 - F. Casas, P. Rochard, A. Rodier, I. Cassar-Malek, S. Marchal-Victorion, R. J. Wiesner, G. Cabello, C. Wrutniak, 1999 A variant form of the nuclear triiodothyronine receptor c-ErbAalpha1 plays a direct role in regulation of mitochondrial RNA synthesis. Mol Cell Biol. 19 79137924 .
11 - E. Castro-Rivera, I. Samudio, S. Safe, 2001 Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol Chem. 276 3085330861 .
12 - E. L. Cavalieri, E. G. Rogan, 2001 Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene. Oncogene 20 79457953 .
13 - D. Chakravarti, , P. Mailander, , K.M. Li, , S. Higginbotham, , H.L. Zhang, , M.L. Gross, , J.L. Meza,
14 - E. L. Cavalieri, D. E. Stack, P. D. Devanesan, R. Todorovic, I. Dwivedy, S. Higginbotham, S. L. Johansson, K. D. Patil, M. L. Gross, J. K. Gooden, R. Ramanathan, R. L. Cerny, E. G. Rogan, 1997 Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci U S A. Sep 94 1093742 .
15 - T.O. Chan, , S.E. Rittenhouse, and P.N. Tsichlis, AKT/PKB and other D3 phosphoinositideregulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. 1999 Annu Rev Biochem 68 9651014 .
16 - G. G. Chen, Z. M. Liu, A. C. Vlantis, G. M. Tse, B. C. Leung, C. A. van Hasselt, 2004 Heme oxygenase-1 protects against apoptosis induced by tumor necrosis factor-alpha and cycloheximide in papillary thyroid carcinoma cells. J Cell Biochem. 92 124656 .
17 - G. G. Chen, A. C. Vlantis, Q. Zeng, C. A. van Hasselt, 2008 Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. Curr Cancer Drug Targets. 8 367377 .
18 - J. Chen, M. Gokhale, Y. Li, M. A. Trush, J. D. Yager, 1998 Enhanced levels of several mitochondrial mRNA transcripts and mitochondrial superoxide production during ethinyl estradiol-induced hepatocarcinogenesis and after estrogen treatment of HepG2 cells. ChenJ.GokhaleM.LiY.TrushM. A.YagerJ. D. (1998) Enhanced levels of several mitochondrial mRNA transcripts and mitochondrial superoxide production during ethinyl estradiol-induced hepatocarcinogenesis and after estrogen treatment of HepG2 cells. Carcinogenesis. . . 19 21872193 .
19 - J. Chen, D. A. Schwartz, T. A. Young, J. S. Norris, J. D. Yager, 1996 Identification of genes whose expression is altered during mitosuppression in livers of ethinyl estradiol-treated female rats. Carcinogenesis. 17 27832786 .
20 - J. Q. Chen, M. Delannoy, C. Cooke, J. D. Yager, 2004 Mitochondrial localization of ERalpha and ERbeta in human MCF7 cells. Am J Physiol. 286:E1011 -E1022.
21 - W. S. Chen, P. Z. Xu, K. Gottlob, M. L. Chen, K. Sokol, T. Shiyanova, I. Roninson, W. Weng, R. Suzuki, K. Tobe, T. Kadowaki, N. Hay, Growth retardation and increased apoptosis in mice with homozygous disruption of the 1 gene. (2001) Genes Dev 15 22038 .
22 - H. Cho, J. Mu, J. K. Kim, J. L. Thorvaldsen, Q. Chu, E. B. Crenshaw, 3 Kaestner, K.H., Bartolomei, M.S., Shulman, G.I. and Birnbaum, M.J. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase AktAKT2 (PKB beta). (2001) Science 292 17281731 .
23 - H. Cho, J. L. Thorvaldsen, Q. Chu, F. Feng, M. J. Birnbaum, 2001 AktAKT1/pkbalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 276 3834952 .
24 - P. J. Coffer, J. R. Woodgett, 1991 Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem. 201 475481 .
25 - Valle. L. Dalla, A. Ramina, S. Vianello, A. Fassina, P. Belvedere, L. Colombo, 1998 Potential for estrogen synthesis and action in human normal and neoplastic thyroid tissues. J. Clin. Endocrinol. Metab. 83 37023709 .
26 - S. R. Datta, A. Brunet, M. E. Greenberg, Cellular survival: a play in three AktAKTs. 1999 Genes Dev. 13 290527 .
27 - K. Dechering, S. Boersma, S. Mosselman, 2000 Estrogen receptors alpha and beta: two receptors of a kind? Curr. Med. Chem. 7 561576 .
28 - C. V. Demonacos, N. Karayanni, E. Hatzoglou, C. Tsiriyiotis, D. A. Spandidos, C. E. Sekeris, 1996 Mitochondrial genes as sites of primary action of steroid hormones. Steroids. 61 226232 .
29 - B. J. Deroo, K. S. Korach, 2006 Estrogen receptors and human disease. J Clin Invest. 116 56170 .
30 - G. M. Dick, A. C. Hunter, K. M. Sanders, 2002 Ethylbromide tamoxifen, a membrane-impermeant antiestrogen, activates smooth muscle calcium-activated large-conductance potassium channels from the extracellular side. Mol Pharmacol. 61 5 110513 .
31 - J. A. Diehl, M. Cheng, M. F. Roussel, C. J. Sherr, 1998 Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12 34993511 .
32 - W. Droge, 2002 Free radicals in the physiological control of cell function. Physiol Rev 82 4795 .
33 - K. L. Dunn, P. S. Espino, B. Drobic, S. He, J. R. Davie, 2005 The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem Cell Biol. 83 114 .
34 - J. A. Enriquez, P. Fernandez-Silva, N. Garrido-Perez, M. J. Lopez-Perez, A. Perez-Martos, J. Montoya, 1999 Direct regulation of mitochondrial RNA synthesis by thyroid hormone. Mol Cell Biol. 19 657670 .
35 - J. A. Fagin, 2004 How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol. 183 24956 .
36 - Q. Felty, 2006 Estrogen-induced DNA synthesis in vascular endothelial cells is mediated by ROS signaling. BMC Cardiovasc Disord 6 1622 .
37 - Q. Felty, K. P. Singh, D. Roy, 2005 Estrogen-induced G1/S transition of G0-arrested estrogen-dependent breast cancer cells is regulated by mitochondrial oxidant signaling. Oncogene 24 488393 .
38 - S. V. Fernandez, I. H. Russo, M. Lareef, B. Balsara, J. Russo, 2005 Comparative genomic hybridization of human breast epithelial cells transformed by estrogen and its metabolites. Int J Oncol. 26 6915 .
39 - E. J. Filardo, J. A. Quinn, K. I. Bland, A. R. Frackelton, Jr , 2000 Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 14 16491660 .
40 - E. J. Filardo, C. T. Graeber, J. A. Quinn, M. B. Resnick, D. Giri, R. A. De Lellis, M. M. Steinhoff, E. Sabo, 2006 Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin. Cancer Res. 12 63596366 .
41 - T. F. Franke, S. I. Yang, T. O. Chan, K. Datta, A. Kazlauskas, D. K. Morrison, D. R. Kaplan, P. N. Tsichlis, The protein kinase encoded by the AktAKT proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. 1995 Cell 2 72736 .
42 - J. S. Foster, R. I. Fernando, N. Ishida, K. I. Nakayama, J. Wimalasena, 2003 Estrogens down-regulate 27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway. J Biol Chem. 278:41355-41366.
43 - G. Garcia-Rostan, A. M. Costa, I. Pereira-Castro, G. Salvatore, R. Hernandez, M. J. Hermsem, et al. 2005 Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 65 1019910207 .
44 - S. George, , J.J. Rochford, , C. Wolfrum, , S.L. Gray, , S. Schinner, , J.C. Wilson, , M.A. Soos, , P.R. Murgatroyd, , R.M. Williams, , C.L. Acerini, , D.B. Dunger, , D. Barford, , A.M. Umpleby, , N.J. Wareham, , H.A. Davies, , A.J. Schafer, , M. Stoffel, , S. O’Rahilly, and I. Barroso, A family with severe insulin resistance and diabetes due to a mutation in AKT2. (2004) Science 304:1325-1328.
45 - C. P. Gilfillan, 2010 Review of the genetics of thyroid tumours: diagnostic and prognostic implications. ANZ Journal of Surgery. 80 3340 .-
46 - A. Grossman, J. Oppenheim, G. Grondin, Jean. P. St, A. R. Beaudoin, 1989 Immunocytochemical localization of the [3H]estradiol-binding protein in rat pancreatic acinar cells. Endocrinology. 124 28572866 .
47 - A. Gutierrez-Hartmann, D. L. Duval, A. P. Bradford, 2007 ETS transcription factors in endocrine systems. Trends Endocrinol Metab. 18 4 1508 .
48 - E. Haas, M. R. Meyer, U. Schurr, I. Bhattacharya, R. Minotti, H. H. Nguyen, A. Heigl, M. Lachat, M. Genoni, M. Barton, 2007 Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension. 49 13581363 .
49 - J. M. Hall, J. F. Couse, K. S. Korach, 2001 The multifaceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem. 276 3686936872 .
50 - D. Handkiewicz-Junak, A. Czarniecka, B. Jarzab, 2010 Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Mol Cell Endocrinol. 322 828 .
51 - Y. Y. He, B. Cai, Y. X. Yang, X. L. Liu, X. P. Wan, 2009 Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Sci. 100 10511061 .
52 - C. Hermenegildo, A. Cano, 2000 Pure anti-oestrogens. Hum Reprod Update. 6 3 23743 .
53 - B. L. Herrmann, B. Saller, O. E. Janssen, P. Gocke, A. Bockisch, H. Sperling, K. Mann, M. Broecker, 2002 Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J. Clin. Endocrinol. Metab. 8 54765484 .
54 - N. C. Hodgson, J. Button, C. C. Solorzano, 2004 Thyroid cancer: is the incidence still increasing? Ann Surg Oncol. 11 10937 .
55 - P. Hou, M. Ji, M. Xing, 2008 Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer. 113 24402447 .
56 - P. Hou, D. Liu, Y. Shan, S. Hu, K. Studeman, S. Condouris, et al. 2007 Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/AktAKT pathway in thyroid cancer. Clin Cancer Res. 13 11611170 .
57 - E. R. Hugo, T. D. Brandebourg, J. G. Woo, J. Loftus, J. W. Alexander, N. Ben-Jonathan, 2008 Bisphenol A at environmentally relevant doses inhibits adiponectin release from human adipose tissue explants and adipocytes. Environ. Health Perspect. 116 16421647 .
58 - T. Ikenoue, K. Inoki, Q. Yang, X. Zhou, K. L. Guan, Essential function 2 TORC2 in PKC and AktAKT turn motif phosphorylation, maturation and signaling. (2008) EMBO J 23 191931 .
59 - A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, M. J. Thun, 2009 Cancer statistics, 2009. CA Cancer J Clin. 59 22549 .
60 - E. V. Jensen, E. R. De Sombre, 1973 Estrogen-receptor interaction. Science. 182 126134 .
61 - K. P. Jones, 1992 Estrogens and progestins: what to use and how to use it. Clin. Obstet. Gynecol. 32 871883 .
62 - P. F. Jones, T. Jakubowicz, F. J. Pitossi, F. Maurer, B. A. Hemmings, 1991 Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci U S A. 88 41714175 .
63 - S. G. Kennedy, E. S. Kandel, T. K. Cross, N. Hay, 1999 AktAKT/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol 19 58005810 .
64 - C. S. Kim, X. Zhu, 2009 Lessons from mouse models of thyroid cancer. KimC. S.ZhuX. (2009) Lessons from mouse models of thyroid cancer. Thyroid. .. 19 131731 .
65 - K. H. Kim, K. Moriarty, J. R. Bender, 2008 Vascular cell signaling by membrane estrogen receptors. Steroids. 73(9-10):8649 .
66 - C. M. Klinge, 2000 Estrogen receptor interaction with co-activators and co-repressors. Steroids 65 22725 .
67 - P. Kossmehl, M. Shakibaei, A. Cogoli, M. Infanger, F. Curcio, J. Schönberger, C. Eilles, J. Bauer, H. Pickenhahn, G. Schulze-Tanzil, M. Paul, D. Grimm, 2003 Weightlessness induced apoptosis in normal thyroid cells and papillary thyroid carcinoma cells via extrinsic and intrinsic pathways. Endocrinology. 144 41729 .
68 - G. Kouniavsky, M. A. Zeiger, 2010 Thyroid tumorigenesis and molecular markers in thyroid cancer. Curr Opin Oncol. 22 239 .
69 - G. G. Kuiper, E. Enmark, M. Pelto-Huikko, S. Nilsson, J. A. Gustafsson, 1996 Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 93 59255930 .
70 - G. G. Kuiper, B. Carlsson, K. Grandien, E. Enmark, J. Häggblad, S. Nilsson, J. A. Gustafsson, 1997 Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 138 863870 .
71 - A. Kumar, C. M. Klinge, R. E. Goldstein, 2010 Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta. Int J Oncol. 36 10671080 .
72 - M. L. Lee, G. G. Chen, A. C. Vlantis, G. M. Tse, B. C. Leung, C. A. van Hasselt, 2005 Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL. Cancer J. 11 113121 .
73 - N. R. Lemoine, E. S. Mayall, F. S. Wyllie, C. J. Farr, D. Hughes, R. A. Padua, V. Thurston, E. D. Williams, D. Wynford-Thomas, 1988 Activated ras oncogenes in human thyroid cancers. Cancer Res. 48 44594463 .
74 - G. Leto, F. M. Tumminello, M. Crescimanno, C. Flandina, N. Gebbia, 2004 Cathepsin D expression levels in non-gynecological solid tumors: clinical and therapeutic implications. Clin Exp Metastasis. 21 91106 .
75 - S. K. Libutti, 2005 Understanding the role of gender in the incidence of thyroid cancer. Cancer J. 11 104105 .
76 - L. P. Lima, I. A. Barros, P. C. Lisbôa, R. L. Araújo, A. C. Silva, D. Rosenthal, A. C. Ferreira, D. P. Carvalho, 2006 Estrogen effects on thyroid iodide uptake and thyroperoxidase activity in normal and ovariectomized rats. Steroids. 71 6539 .
77 - M. M. Liu, C. Albanese, C. M. Anderson, K. Hilty, P. Webb, R. M. Uht, R. H. Price, R. G. Jr Pestell, P. J. Kushner, 2002 Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem. 277 2435324360 .
78 - Z. Liu, P. Hou, M. Ji, H. Guan, K. Studeman, K. Jensen, V. Vasko, A. K. El -Naggar, M. Xing, 2008 Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J. Clin. Endocrinol. Metab. 93 31063116 .
79 - Q. Lu, H. Ebling, J. Mittler, W. E. Baur, R. H. Karas, 2002 MAP kinase mediates growth factor-induced nuclear translocation of estrogen receptor alpha. FEBS Lett. 516(1-3):1-8.Manning BD, and Cantley LC. (2007) AKT/PKB signaling: navigating downstream. Cell 129 126174 .
80 - Volsi. V. A. Li, 2011 Papillary thyroid carcinoma: an update. Mod Pathol. Suppl 2:S19 .
81 - A. Machens, S. Hauptmann, H. Dralle, 2006 Disparities between male and female patients with thyroid cancers: sex difference or gender divide? Clin Endocrinol (Oxf). 65 5005 .
82 - D. Manole, B. Schildknecht, B. Gosnell, E. Adams, M. Derwahl, 2001 Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J Clin Endocrinol Metab. 86 10721077 .
83 - L. D. Mayo, D. B. Donner, 2001 A phosphatidylinositol 3-kinase/AktAKT pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A. 98 11598603 .
84 - K. A. Miller, N. Yeager, K. Baker, X. H. Liao, S. Refetoff, A. Di Cristofano, 2009 Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res. 69 36893694 .
85 - R. K. I. I. Moats, V. D. Ramirez, 2000 Electron microscopic visualization of membrane-mediated uptake and translocation of estrogen-BSA:colloidal gold by hep G2 cells. J Endocrinol. 166 631647 .
86 - P. Monje, R. Boland, 2001 Subcellular distribution of native estrogen receptor alpha and beta isoforms in rabbit uterus and ovary. J Cell Biochem. 82 467479 .
87 - P. Monje, S. Zanello, M. Holick, R. Boland, 2001 Differential cellular localization of estrogen receptor alpha in uterine and mammary cells. Mol Cell Endocrinol. 181 117129 .
88 - M. Mori, M. Naito, H. Watanabe, N. Takeichi, K. Dohi, A. Ito, 1990 Effects of sex difference, gonadectomy, and estrogen on N-methyl-N-nitrosourea induced rat thyroid tumors. Cancer Res. 50 76627 .
89 - R. C. Muise-Helmericks, H. L. Grimes, A. Bellacosa, S. E. Malstrom, P. N. Tsichlis, N. Rosen, 1998 Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/AktAKT-dependent pathway. J. Biol. Chem. 273 2986429872 .
90 - R. E. Müller, T. C. Johnston, H. H. Wotiz, 1979 Binding of estradiol to purified uterine plasma membranes. J Biol Chem. 254 16 7895900 .
91 - R. L. Neff, W. B. Farrar, R. T. Kloos, K. D. Burman, 2008 Anaplastic thyroid cancer. Endocrinol Metab Clin North Am. 37 52538 .
92 - Y. E. Nikiforov, 2008 Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol. 2:S37 -S43.
93 - B. F. O’Dowd, T. Nguyen, A. Marchese, R. Cheng, K. R. Lynch, H. H. Heng, L. F. Kolakowski , JrJr S. R. George, 1998 Discovery of three novel G-protein-coupled receptor genes. Genomics. 47 310313 .
94 - C. Owman, P. Blay, C. Nilsson, S. J. Lolait, 1996 Cloning of human cDNA encoding a novel heptahelix receptor expressed in Burkitt’s lymphoma and widely distributed in brain and peripheral tissues. Biochem. Biophys. Res. Commun. 228 285292 .
95 - A. Pedram, M. Razandi, E. R. Levin, 2006 Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 20 19962009 .
96 - R. G. Pestell, C. Albanese, A. T. Reutens, J. E. Segall, R. J. Lee, A. Arnold, 1999 The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev. 20 501534 .
97 - G. Posern, R. Treisman, 2006 Actin’ together: serum response factor, its cofactors and the link to signal transduction. Trends Cell Biol. 16 11 58896 .
98 - S. Rajoria, R. Suriano, A. Shanmugam, Y. L. Wilson, S. P. Schantz, J. Geliebter, R. K. Tiwari, 2010 Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid. 20 3341 .
99 - P. J. Roberts, C. J. Der , 2007 Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26 3291310 .
100 - R. J. Ruggiero, F. E. Likis, 2002 Estrogen: physiology, pharmacology, and formulations for replacement therapy. J. Midwifery Womens Health. 47 130138 .
101 - D. D. Sarbassov, D. A. Guertin, S. M. Ali, D. M. Sabatini, Phosphorylation and regulation of AktAKT/PKB by the rictor-mTOR complex. 2005 Science 18 10981101 .
102 - C. E. Sekeris, 1990 The mitochondrial genome: a possible primary site of action of steroid hormones. In Vivo. 4 317320 .
103 - R. C. Smallridge, L. A. Marlow, J. A. Copland, 2009 Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 16 1744 .
104 - R. X. Song, R. J. Santen, 2003 Apoptotic action of estrogen. Apoptosis. 8 5560 .
105 - L. Speroff, R. H. Glass, N. G. Kase, 1999 Clin. Gynecol. Endocrinol. Infert. (6th ed). Lippincott Williams & Wilkins: Philadelphia.
106 - J. D. Stender, J. Frasor, B. Komm, K. C. Chang, W. L. Kraus, B. S. Katzenellenbogen, 2007 Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Mol Endocrinol. 21 211223 .
107 - C. Stirone, S. P. Duckles, D. N. Krause, V. Procaccio, 2005 Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels. Mol Pharmacol. 68 959965 .
108 - A. Strom, J. Hartman, J. S. Foster, S. Kietz, J. Wimalasena, J. A. Gustafsson, 2004 Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc. Natl. Acad. Sci. USA. 101 15661571 .
109 - Y. Takada, C. Kato, S. Kondo, R. Korenaga, J. Ando, 1997 Cloning of cDNAs encoding G protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress. Biochem. Biophys. Res. Commun. 240 737741 .
110 - J. R. Testa, A. A. K. T. Bellacosa, a. plays, role. central, tumorigenesis. in, 2001 Proc. Natl. Acad. Sci. USA 98 1098310985 .
111 - A. Thiruvengadam, P. Govindarajulu, M. M. Aruldhas, 2003 Modulatory effect of estradiol and testosterone on the development of N-nitrosodiisopropanolamine induced thyroid tumors in female rats. Endocr Res. 29 4351 .
112 - V. V. Vasko, M. Saji, 2007 Molecular mechanisms involved in differentiated thyroid cancer invasion and metastasis. Curr Opin Oncol. 19 1117 .
113 - A. Vivacqua, D. Bonofiglio, L. Albanito, A. Madeo, V. Rago, A. Carpino, et al. 2006 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein-coupled receptor GPR30. Mol Pharmacol. 70 14141423 .
114 - F. Wang, W. Porter, W. Xing, T. K. Archer, S. Safe, 1997 Identification of a functional imperfect estrogen-responsive element in the 5’- promoter region of the human cathepsin D gene. Biochemistry. 36 77937801 .
115 - Y. Wang, P. Hou, H. Yu, W. Wang, M. Ji, S. Zhao, et al. 2007 High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab. 92 23872390 .
116 - C. S. Watson, R. A. Alyea, Y. J. Jeng, M. Y. Kochukov, 2007 Nongenomic actions of low concentration estrogens and xenoestrogens on multiple tissues. Mol Cell Endocrinol 274 17 .
117 - Z. Weihua, , S. Saji, , S. Makinen, , G. Cheng, , E.V. Jensen, , M. Warner, and J.A. Gustafsson, Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus. Proc. Natl. Acad. Sci. USA. 97:5936-5941.
118 - D. J. Withers, J. S. Gutierrez, H. Towery, D. J. Burks, J. M. Ren, S. Previs, Y. Zhang, D. Bernal, S. Pons, G. I. Shulman, S. Bonner-Weir, M. F. White, 1998 Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391 900904 .
119 - C. W. Wong, C. Mc Nally, E. Nickbarg, B. S. Komm, B. J. Cheskis, 2002 Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci U S A. 99 1478314788 .
120 - C. Wrutniak, I. Cassar-Malek, S. Marchal, A. Rascle, S. Heusser, J. M. Keller, J. Flechon, M. Dauca, J. Samarut, J. Ghysdael, G. Cabello, 1995 A 43-kDa protein related to c-Erb A alpha 1 is located in the mitochondrial matrix of rat liver. J Biol Chem. 270 1634716354 .
121 - M. Xing, 2005 BRAF mutation in thyroid cancer. Endocr. Relat. Cancer. 12 245262 .
122 - N. Yeager, C. Brewer, K. Q. Cai, X. X. Xu, A. Di Cristofano, 2008 mTOR is the key effector of PI3K-initiated proliferative signals in the thyroid follicular epithelium. Cancer Res. 68 444449 .
123 - N. Yeager, A. Klein-Szanto, S. Kimura, A. Di Cristofano, 2007 Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. Cancer Res. 67 95966 .
124 - Q. Zeng, G. G. Chen, A. C. Vlantis, C. A. van Hasselt, 2007 Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway. Cell Prolif. 40 92135 .
125 - Z. Zhang, L. Duan, X. Du, Ma H. , I. Park, C. Lee, J. Zhang, J. Shi, 2008 The proliferative effect of estradiol on human prostate stromal cells is mediated through activation of ERK. ZhangZ.DuanL.DuX.MaH.ParkI.LeeC.ZhangJ.ShiJ. (2008) The proliferative effect of estradiol on human prostate stromal cells is mediated through activation of ERK. Prostate. . . 68 508516 .